Lupin Limited has informed the Exchange regarding a press release dated July 04, 2025, titled "Lupin Launches Ipratropium Bromide Nasal Solution (Nasal Spray), 0.03% and 0.06%in the United States".
LUPIN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Lupin has launched Ipratropium Bromide Nasal Solution (Nasal Spray) in two strengths — 0.03% and 0.06% — in the United States. The product is a generic version of Boehringer Ingelheim's Atrovent® Nasal Spray, indicated for relief of runny nose caused by allergies, common cold, and perennial rhinitis. The reference brand (Atrovent®) had estimated annual US sales of USD 63 million (IQVIA MAT May 2025). The launch strengthens Lupin's US respiratory portfolio, which is one of its key therapy areas.
This adds a new product in Lupin's US generic business, tapping a USD 63 million market opportunity. However, actual revenue gains will depend on competition, pricing pressure, and the share Lupin captures in this generic market — meaningful but not transformative on its own.